Core Viewpoint - Lixte Biotechnology Holdings, Inc. has successfully closed a private placement raising approximately $5.0 million through the sale of shares and warrants, aimed at supporting its cancer drug development efforts [1][3]. Group 1: Private Placement Details - The offering included the sale of 2,382,084 shares of Common Stock (or Pre-Funded Warrants), 3,573,130 shares of Series B Convertible Preferred Stock, and 6,355,214 Common Warrants [2]. - The Pre-Funded Warrants are immediately exercisable at a price of $0.00001, while the Common Warrants have an initial exercise price of $1.00 per share and expire 60 months after the resale registration statement is effective [2]. - The gross proceeds of approximately $5.0 million consist of $4.0 million paid at closing and $1.0 million to be paid upon the effectiveness of the resale registration statement [3]. Group 2: Use of Proceeds - The net proceeds from the offering, along with existing cash, are intended for general corporate purposes and working capital [3]. Group 3: Company Overview - Lixte Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical company focused on developing new cancer therapies, particularly its lead compound LB-100, which has shown promise in enhancing chemotherapy and immunotherapy outcomes [6][7]. - LB-100 is part of a new treatment paradigm in cancer biology known as activation lethality, with ongoing proof-of-concept clinical trials for various cancer types [7].

SEOUL, South Korea, July 2, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI for cancer diagnostics and therapeutics, today announced a collaboration with Microsoft to accelerate the delivery of AI-powered healthcare solutions. In conjunction with their recent acquisition of Volpara, a Microsoft Industry Health Certified Partner, this collaboration will give health professionals globally access to tools that will assist in the detection of cancer. Lunit and Microsoft collaborate to d ...

Core Insights - The combination treatment of mTNX-1700 with anti-PD1 antibody has shown increased survival and decreased metastases in animal models of gastric cancer compared to anti-PD1 treatment alone [1][3] - mTNX-1700 activates cancer-killing CD8+ T cells and limits neutrophil-mediated immune evasion, indicating its potential in overcoming resistance to anti-PD-1 immunotherapy [1][2] Company Overview - Tonix Pharmaceuticals Holding Corp. is a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, focusing on immunology and oncology [1][7] - The company is developing TNX-1700, a fusion protein for the treatment of gastric and colorectal cancers, under a license from Columbia University [4][5] Research Findings - The study published in Cancer Cell demonstrates that mTNX-1700 in combination with anti-PD-1 therapy shrank primary tumors, reduced liver and lung metastases, and increased survival in mouse models [2][3] - The research highlights the role of Trefoil Factor 2 (TFF2) in reducing immunosuppressive neutrophils and enhancing anti-tumoral CD8+ T cell responses [3][4] Future Development - Tonix Pharmaceuticals aims to further develop TNX-1700 to address the challenges of anti-PD-1 resistant cancers, with ongoing studies to identify potential clinical biomarkers [2][3] - The collaboration with Columbia University is expected to enhance understanding of TFF2's role in the tumor microenvironment and its impact on immunotherapy resistance [3][4]

Core Insights - Amgen's stock rose over 4% following positive news regarding its investigational stomach cancer drug, bemarituzumab, which outperformed the S&P 500 index that slid by 0.1% [1][2] Group 1: Drug Development - Bemarituzumab, in combination with chemotherapy, met its primary endpoint of overall survival in a phase 3 clinical trial, showing favorable results compared to patients receiving only a placebo [2][4] - The study involved 547 patients with unresectable locally advanced or metastatic gastric or gastroesophageal junction cancer, highlighting the significance of the drug in addressing a major health issue, as gastric cancer is the fifth-leading cause of cancer-related death globally, with over 650,000 fatalities [4] Group 2: Analyst Reactions - Analysts reacted positively to the trial results, with Piper Sandler's David Amsellem maintaining an overweight (buy) recommendation and setting a price target of $328 per share, indicating confidence in the drug's potential despite some concerns [5] - The overall sentiment among analysts suggests that Amgen may be on the verge of a successful drug launch, with optimism surrounding the advancements in cancer treatment [6]

Endocrine Disruptors Overview - Endocrine disruptors are molecules capable of disrupting the hormonal system [8] - Hormones are chemical substances produced by glands that act as keys interacting with specific receptors [8][9] - These disruptors can interfere with hormone effects, leading to various health risks [11] Health Risks Associated with Endocrine Disruptors - Potential health risks include hypertension, cancers (prostate, testicles, breast, ovaries), masculinization in women, and feminization in men [12][13] - Sperm count has decreased by half from 1978 to 2020 [13] - Endocrine disruptors can affect puberty, potentially causing precocious puberty in young girls [14] Sources and Presence of Endocrine Disruptors - Common sources include bisphenol, phthalates in plastics, parabens, heavy metals, preservatives (BHA, BHT), and pesticides [18] - Found in medications, plastic packaging, canned goods, paints, and cosmetics [18][19] - Present in food items like corn, rice, dried/smoked fish, and fresh tomatoes, as shown by studies in Burkina Faso [21] Mitigation Strategies - Reduce exposure by being cautious with street medications and natural aphrodisiacs [23] - Pay attention to pesticides in food and choose cosmetics carefully [23][24] - Be mindful of plastic packaging and food additives [24] - Adopt new behaviors and pass them on to children [25] Other Disruptors - Alcohol, excess sugar and fat, mycotoxins, shisha, and cigarettes (containing approximately 280 different molecules in their smoke) are also disruptors [25]

Core Insights - Processa Pharmaceuticals is focusing on oncology assets with strong differentiation and commercial opportunity to enhance shareholder value [4][9] - The company is actively enrolling patients in a Phase 2 clinical trial for its lead oncology asset, PCS6422, targeting metastatic breast cancer, with initial data expected in the second half of 2025 [2][7] - Processa has signed a binding term sheet with Intact Therapeutics for PCS12852, which could yield up to $454 million in milestone payments and a 12% royalty on future sales [7] Company Updates - The company is streamlining its development pipeline and optimizing capital allocation to focus on programs with the highest potential for clinical success [2][4] - A new adaptive pivotal Phase III study for PCS499 is being designed, following preliminary positive results in kidney disease [7] - Processa has terminated the license agreement for PCS3117 due to high costs and time requirements, returning rights to the original licensor [7] Financial and Strategic Developments - Processa has strengthened its balance sheet with a $7 million capital infusion [6] - The company is establishing a dedicated subsidiary for PCS499 to enhance strategic flexibility in capital raising and partnership exploration [7] - An investor webinar is scheduled for July 9, 2025, to discuss the company's strategic pipeline realignment and milestones [5]

Core Points - TuHURA Biosciences, Inc. has been added to the Russell 3000® Index and automatically included in the Russell 2000® Index as part of the 2025 annual reconstitution, effective June 27, 2025 [1][2] - The inclusion in the Russell indexes signifies the company's progress in its first year as a publicly traded entity and reflects its potential for continued development [2] - TuHURA is currently enrolling patients in a Phase 3 accelerated approval trial of its lead product IFx-2.0, which is being tested as an adjunctive therapy to Keytruda® for advanced or metastatic Merkel cell carcinoma [2][11] - The company has also acquired a novel anti-VISTA antibody from Kineta, Inc. and plans to advance it into a Phase 2 clinical trial for treating NMPL1-mutated Acute Myeloid Leukemia [2] Company Overview - TuHURA Biosciences, Inc. is focused on developing novel technologies to overcome resistance to cancer immunotherapy, addressing both primary and acquired resistance [10] - The company's lead product, IFx-2.0, is designed to enhance the effectiveness of checkpoint inhibitors [11] - TuHURA is also leveraging its Delta Opioid Receptor technology to create bi-specific antibody drug conjugates aimed at inhibiting immune suppression in the tumor microenvironment [12]

LONDON and PHILADELPHIA, July 01, 2025 (GLOBE NEWSWIRE) -- Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs, today announces the appointment of David Liebowitz, M.D., Ph.D. as Chief Medical Officer (CMO) and Yulii Bogatyrenko as an advisor in business development. Dr. Liebowitz will lead the Company's clinical strategy and execution as it continues to advance its pipeline of targeted cancer therapies and Mr. Bogatyrenko will add additional strength to the ...

[Music] You have a war to fight. A small sentence, just five words, but it changed everything. I was lying in a hospital bed when the doctor examined my test results and said those words to me.My 8-year-old self was baffled. Seriously, me fighting a war. What war.At eight years old, how was I supposed to fight something as big as a war. Wars were things I read about in history books, saw on the news, or heard about in the stories my grandfather told me. But I was just a kid.It turns out that the war I had t ...

When I was 17, I left home for college. One month later, my mother was diagnosed with cancer for the second time. That was a scary time for all of us.But her journey in fighting this battle and a journey we took together as a family forever changed the way I think about resilience. I learned that resilience is not about the actions of a single person. It's the work of a community, a family. It's about the relationships we form with others.And these relationships, I learned, are the key to resilience. I've c ...